Biologics News

The U.S. Patent and Trademark Office issued a fundamental patent for ISTO Technologies’ InQu Bone Graft Extender and Substitute.

AMSTERDAM — Results of a prospective pilot study of cervical intervertebral disc allograft transplantations performed in 24 patients indicate there were signs of bony endplate fusion and preserved neurological status at a maximum follow-up of 10 years, according to a study presented at SpineWeek 2012, here.

ORLANDO — Protein-rich plasma injection showed a significant reduction in pain and improved function at early follow-up in patients with patellar tendinopathy, according to a recently presented study.

Piramal Healthcare Bio-Orthopaedics, a division of Piramal Healthcare Limited, announced in a press release positive data from their phase III clinical trial of BST-CarGel at the International Cartilage Repair Society World Congress 2012.

MONTREAL — Results of a meta-analysis presented here indicated superior short- and mid-term outcomes with autologous chondrocyte implantation procedures compared to microfracture.

MONTREAL — Although platelet-rich plasma is useful in the repair of some musculoskeletal injuries, one researcher speaking at the International Cartilage Repair Society World Congress 2012, here, noted it is critical to understand that the material is more than just platelets and its ability to aid in healing is not based only on platelet concentration.

Regentis Biomaterials Ltd., a manufacturer of hydrogels for tissue regeneration, received $10 million from investors, allowing the company to continue promoting GelrinC and expand itself in Europe.

A study of more than 4,000 patients with osteoarthritis of the knee indicates that viscosupplementation administered in either a large-dose single injection or three, smaller dose injections significantly reduces pain and improves function at 6 months.

A joint venture between an Essex Woodlands investor group and Smith & Nephew has led to the creation of Bioventus, LLC. The new company was formed from Smith & Nephew’s Biologics and Clinical Therapies division, incorporating 500 U.S. employees.

Biologics are substances that enhance or quicken healing in structures, such as bones, ligaments, tendons and muscles. This area of orthopedics involves the use of matrix materials, growth factors, and gene and cell therapies used alone or in conjunction with orthopedic devices.